Browse CTSG

Summary
SymbolCTSG
Namecathepsin G
Aliases CG; CATG
Chromosomal Location14q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell surface
Domain PF00089 Trypsin
Function

Serine protease with trypsin- and chymotrypsin-like specificity. Cleaves complement C3. Has antibacterial activity against the Gram-negative bacterium P.aeruginosa, antibacterial activity is inhibited by LPS from P.aeruginosa, Z-Gly-Leu-Phe-CH2Cl and phenylmethylsulfonyl fluoride.

> Gene Ontology
 
Biological Process GO:0001906 cell killing
GO:0001909 leukocyte mediated cytotoxicity
GO:0001990 regulation of systemic arterial blood pressure by hormone
GO:0001991 regulation of systemic arterial blood pressure by circulatory renin-angiotensin
GO:0002002 regulation of angiotensin levels in blood
GO:0002003 angiotensin maturation
GO:0002237 response to molecule of bacterial origin
GO:0002443 leukocyte mediated immunity
GO:0002444 myeloid leukocyte mediated immunity
GO:0002446 neutrophil mediated immunity
GO:0003013 circulatory system process
GO:0003044 regulation of systemic arterial blood pressure mediated by a chemical signal
GO:0003073 regulation of systemic arterial blood pressure
GO:0003081 regulation of systemic arterial blood pressure by renin-angiotensin
GO:0008015 blood circulation
GO:0008217 regulation of blood pressure
GO:0009620 response to fungus
GO:0010817 regulation of hormone levels
GO:0016485 protein processing
GO:0016486 peptide hormone processing
GO:0022617 extracellular matrix disassembly
GO:0030198 extracellular matrix organization
GO:0031640 killing of cells of other organism
GO:0032496 response to lipopolysaccharide
GO:0035821 modification of morphology or physiology of other organism
GO:0042445 hormone metabolic process
GO:0042742 defense response to bacterium
GO:0043062 extracellular structure organization
GO:0043900 regulation of multi-organism process
GO:0043901 negative regulation of multi-organism process
GO:0043903 regulation of symbiosis, encompassing mutualism through parasitism
GO:0044110 growth involved in symbiotic interaction
GO:0044116 growth of symbiont involved in interaction with host
GO:0044117 growth of symbiont in host
GO:0044126 regulation of growth of symbiont in host
GO:0044130 negative regulation of growth of symbiont in host
GO:0044144 modulation of growth of symbiont involved in interaction with host
GO:0044146 negative regulation of growth of symbiont involved in interaction with host
GO:0044364 disruption of cells of other organism
GO:0045926 negative regulation of growth
GO:0050830 defense response to Gram-positive bacterium
GO:0050832 defense response to fungus
GO:0050886 endocrine process
GO:0051604 protein maturation
GO:0051702 interaction with symbiont
GO:0051817 modification of morphology or physiology of other organism involved in symbiotic interaction
GO:0051818 disruption of cells of other organism involved in symbiotic interaction
GO:0051851 modification by host of symbiont morphology or physiology
GO:0051852 disruption by host of symbiont cells
GO:0051873 killing by host of symbiont cells
GO:0051883 killing of cells in other organism involved in symbiotic interaction
GO:0060177 regulation of angiotensin metabolic process
GO:0070942 neutrophil mediated cytotoxicity
GO:0070943 neutrophil mediated killing of symbiont cell
GO:0070944 neutrophil mediated killing of bacterium
GO:0070946 neutrophil mediated killing of gram-positive bacterium
GO:0098542 defense response to other organism
Molecular Function GO:0004175 endopeptidase activity
GO:0004252 serine-type endopeptidase activity
GO:0005539 glycosaminoglycan binding
GO:0008201 heparin binding
GO:0008236 serine-type peptidase activity
GO:0017171 serine hydrolase activity
GO:1901681 sulfur compound binding
Cellular Component GO:0030141 secretory granule
GO:0099503 secretory vesicle
> KEGG and Reactome Pathway
 
KEGG hsa04080 Neuroactive ligand-receptor interaction
hsa04142 Lysosome
hsa04614 Renin-angiotensin system
Reactome R-HSA-1592389: Activation of Matrix Metalloproteinases
R-HSA-6803157: Antimicrobial peptides
R-HSA-1474228: Degradation of the extracellular matrix
R-HSA-1474244: Extracellular matrix organization
R-HSA-168256: Immune System
R-HSA-168249: Innate Immune System
R-HSA-2022377: Metabolism of Angiotensinogen to Angiotensins
R-HSA-392499: Metabolism of proteins
R-HSA-6798695: Neutrophil degranulation
R-HSA-2980736: Peptide hormone metabolism
R-HSA-381426: Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)
Summary
SymbolCTSG
Namecathepsin G
Aliases CG; CATG
Chromosomal Location14q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between CTSG and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between CTSG and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
23147993Acute Myeloid LeukemiaPromote immunityWe showed killing of primary AML by CG1-CTL, but not normal bone marrow. Blocking HLA-A*0201 abrogated CG1-CTL-mediated cytotoxicity, further confirming HLA-A*0201-dependent killing. Finally, we showed functional CG1-CTLs in peripheral blood from AML patients following allogeneic stem cell transplantation. CG is aberrantly expressed and processed in AML and is a novel immunotherapeutic target that warrants further development.
Summary
SymbolCTSG
Namecathepsin G
Aliases CG; CATG
Chromosomal Location14q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of CTSG in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolCTSG
Namecathepsin G
Aliases CG; CATG
Chromosomal Location14q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of CTSG in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.7360.334
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.3990.771
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.950.323
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.0250.975
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.4910.742
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.6920.652
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.0480.963
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.4140.783
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.5720.718
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 481.1340.241
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 282.3760.0484
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.6280.0475
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of CTSG in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27730001
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27590001
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.707.71
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 382707.4-7.40.169
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 221307.7-7.70.371
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 161407.1-7.10.467
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 111307.7-7.71
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 51208.3-8.31
Summary
SymbolCTSG
Namecathepsin G
Aliases CG; CATG
Chromosomal Location14q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CTSG. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolCTSG
Namecathepsin G
Aliases CG; CATG
Chromosomal Location14q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CTSG. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CTSG.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolCTSG
Namecathepsin G
Aliases CG; CATG
Chromosomal Location14q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CTSG. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolCTSG
Namecathepsin G
Aliases CG; CATG
Chromosomal Location14q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of CTSG expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolCTSG
Namecathepsin G
Aliases CG; CATG
Chromosomal Location14q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between CTSG and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolCTSG
Namecathepsin G
Aliases CG; CATG
Chromosomal Location14q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting CTSG collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting CTSG.
ID Name Drug Type Targets #Targets
DB02360Bis-Napthyl Beta-Ketophosphonic AcidSmall MoleculeCTSG1
DB040162-[3-({Methyl[1-(2-Naphthoyl)Piperidin-4-Yl]Amino}Carbonyl)-2-Naphthyl]-1-(1-Naphthyl)-2-Oxoethylphosphonic AcidSmall MoleculeCMA1, CTSG2